Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/aim-immunotech-inc">AIM ImmunoTech </a>is a clinical-stage immuno-pharma company centered on the development of its lead drug candidate, Ampligen (rintatolimod), a first-in-class dsRNA and selective TLR3 agonist, for various cancers, viral diseases, and immune disorders.</li>
  <li>The company's primary focus is on advancing Ampligen for the treatment of late-stage pancreatic cancer, with promising interim data from the Phase 2 DURIPANC study in combination with AstraZeneca's durvalumab. Topline results are anticipated in Q1 2027.</li>
  <li>AIM faces significant financial and clinical risks as a micro-cap biotechnology company with a history of net losses and reliance on equity financing to fund its research and development activities. The successful commercialization of Ampligen is critical for its long-term viability.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
AIM ImmunoTech is a clinical-stage immuno-pharma company centered on the development of its lead drug candidate, Ampligen (rintatolimod), a first-in-class dsRNA and selective TLR3 agonist, for various cancers, viral diseases, and immune disorders.
  The company's primary focus is on advancing Ampligen for the treatment of late-stage pancreatic cancer, with promising interim data from the Phase 2 DURIPANC study in combination with AstraZeneca's durvalumab. Topline results are anticipated in Q1 2027.
  AIM faces significant financial and clinical risks as a micro-cap biotechnology company with a history of net losses and reliance on equity financing to fund its research and development activities. The successful commercialization of Ampligen is critical for its long-term viability.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: AIM ImmunoTech  (AIM US) - Aug 2026

United States

AIM ImmunoTech Inc. is an immuno-pharma company. The Company focuses onthe research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. AIM ImmunoTech operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: AIM ImmunoTech (AIM US) - Aug 2026

AIM ImmunoTech is a clinical-stage immuno-pharma company centered on the development of its lead drug candidate, Ampligen (rintatolimod), a...

αSK Primers